|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/22 Y-mAbs Therapeutics, Inc. 10-K 12/31/21 93:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.78M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 46K
3: EX-21.1 Subsidiaries List HTML 25K
4: EX-23 Consent of Expert or Counsel HTML 25K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
14: R1 Document and Entity Information HTML 95K
15: R2 Consolidated Balance Sheets HTML 123K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
17: R4 Consolidated Statements of Net Loss and HTML 98K
Comprehensive Loss
18: R5 Consolidated Statements of Changes in HTML 79K
Stockholders' Equity
19: R6 Consolidated Statements of Cash Flows HTML 110K
20: R7 Organization and Description of Business HTML 29K
21: R8 Basis of Presentation HTML 32K
22: R9 Summary of Significant Accounting Policies HTML 120K
23: R10 Product Revenue HTML 62K
24: R11 Net Loss Per Share HTML 50K
25: R12 Inventory HTML 43K
26: R13 Intangible Assets HTML 28K
27: R14 Accrued Liabilities HTML 46K
28: R15 License Agreements and Commitments HTML 159K
29: R16 Stockholders' Equity HTML 38K
30: R17 Share-Based Compensation HTML 109K
31: R18 Related Party Transactions HTML 29K
32: R19 Income Taxes HTML 141K
33: R20 Other Benefits HTML 28K
34: R21 Gain From Sale of Priority Review Voucher HTML 28K
35: R22 Summary of Significant Accounting Policies HTML 168K
(Policies)
36: R23 Summary of Significant Accounting Policies HTML 71K
(Tables)
37: R24 Product Revenue (Tables) HTML 57K
38: R25 Net Loss Per Share (Tables) HTML 48K
39: R26 Inventory (Tables) HTML 43K
40: R27 Accrued Liabilities (Tables) HTML 45K
41: R28 License Agreements and Commitments (Tables) HTML 146K
42: R29 Share-Based Compensation (Tables) HTML 103K
43: R30 Income Taxes (Tables) HTML 144K
44: R31 BASIS OF PRESENTATION - Accumulated deficit HTML 29K
(Details)
45: R32 BASIS OF PRESENTATION - Secondary public offering HTML 39K
(Details)
46: R33 BASIS OF PRESENTATION - Cash and cash equivalents HTML 28K
(Details)
47: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 34K
Concentration of Credit Risk (Details)
48: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 44K
Value Measurement (Details)
49: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Operating Leases (Details)
50: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 38K
Property and Equipment (Details)
51: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Income Taxes (Details)
52: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 54K
Revenue Recognition (Details)
53: R40 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 35K
Research and development (Details)
54: R41 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 33K
policies (Details)
55: R42 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 62K
Recently issued accounting pronouncements
(Details)
56: R43 PRODUCT REVENUE - Discounts and Allowances HTML 64K
(Details)
57: R44 PRODUCT REVENUE - Concentrations (Details) HTML 37K
58: R45 NET LOSS PER SHARE - Basic and diluted (Details) HTML 53K
59: R46 NET LOSS PER SHARE - Anti-dilutive securities HTML 28K
(Details)
60: R47 Inventory (Details) HTML 35K
61: R48 Intangible Assets (Details) HTML 30K
62: R49 Accrued Liabilities (Details) HTML 40K
63: R50 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 86K
Agreement (Details)
64: R51 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 64K
MabVax License Agreement (Details)
65: R52 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 47K
agreements (Details)
66: R53 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 65K
agreements (Details)
67: R54 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 35K
(Details)
68: R55 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 41K
maturities (Details)
69: R56 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 30K
and discount rate (Details)
70: R57 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 45K
Preferred Stock (Details)
71: R58 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 82K
non-employees (Details)
72: R59 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 40K
(Details)
73: R60 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 36K
74: R61 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 46K
75: R62 SHARE-BASED COMPENSATION - Stock-based HTML 41K
compensation expense (Details)
76: R63 SHARE-BASED COMPENSATION - Stock Option Valuation HTML 45K
(Details)
77: R64 SHARE-BASED COMPENSATION - Stock option activity HTML 67K
(Details)
78: R65 SHARE-BASED COMPENSATION - Stock option HTML 32K
unrecognized compensation (Details)
79: R66 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 55K
Activity (Details)
80: R67 Related Party Transactions (Details) HTML 43K
81: R68 INCOME TAXES - Loss before income taxes (Details) HTML 42K
82: R69 INCOME TAXES - Provision for (Benefit From) Income HTML 43K
Taxes (Details)
83: R70 INCOME TAXES - Reconciliation of Income Taxes HTML 53K
(Details)
84: R71 INCOME TAXES - Deferred assets (Liabilities) HTML 56K
(Details)
85: R72 INCOME TAXES - Net Operating Loss Carryforwards HTML 39K
(Details)
86: R73 INCOME TAXES - Uncertain tax positions (Details) HTML 34K
87: R74 Other Benefits (Details) HTML 29K
88: R75 Gain From Sale of Priority Review Voucher HTML 38K
(Details)
91: XML IDEA XML File -- Filing Summary XML 168K
89: XML XBRL Instance -- ymab-20211231x10k_htm XML 2.00M
90: EXCEL IDEA Workbook of Financial Reports XLSX 114K
10: EX-101.CAL XBRL Calculations -- ymab-20211231_cal XML 177K
11: EX-101.DEF XBRL Definitions -- ymab-20211231_def XML 637K
12: EX-101.LAB XBRL Labels -- ymab-20211231_lab XML 1.38M
13: EX-101.PRE XBRL Presentations -- ymab-20211231_pre XML 1.07M
9: EX-101.SCH XBRL Schema -- ymab-20211231 XSD 201K
92: JSON XBRL Instance as JSON Data -- MetaLinks 428± 622K
93: ZIP XBRL Zipped Folder -- 0001558370-22-002567-xbrl Zip 738K
EXHIBIT 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Y-mAbs Therapeutics, Inc. (the “Company”) hereby certifies, to his knowledge, that:
| (i) | the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
| (ii) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| |
Dated: March 1, 2022 | /s/ Bo Kruse |
| Name: Bo Kruse |
| Title: EVP and Chief Financial Officer (Principal Financial Officer) |
1
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/1/22 | None on these Dates | ||
| For Period end: | 12/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA 2/19/21 Y-mAbs Therapeutics, Inc. 8-K:7,8,9 2/17/21 15:2.7M Toppan Merrill/FA 12/22/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/17/20 11:674K Toppan Merrill/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 10/08/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 10/07/20 11:294K Toppan Merrill/FA 4/21/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 4/15/20 2:348K Toppan Merrill/FA 12/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/13/19 3:170K Toppan Merrill/FA 9/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 9/13/19 2:129K Toppan Merrill/FA 9/07/18 Y-mAbs Therapeutics, Inc. S-1/A 5:4.4M Toppan Merrill-FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |